Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VB18214
- Development stage
- Preclinical
- Lead developer
- Shenzhen Yangli Pharmaceutical Technology
01
Overview
VB18214: sourced facts only. name: "Here, we present VB18214 as a novel and selective CDK2 inhibitor." [DOI:10.1158/1538-7445.am2025-3021]; target: "Here, we present VB18214 as a novel and selective CDK2 inhibitor." [DOI:10.1158/1538-7445.am2025-3021]; developer: "Shenzhen Yangli Pharma. Tech. Co., Ltd., Shanghai, China." [DOI:10.1158/1538-7445.am2025-3021]; stage: "In CCNE1-amplified OVCAR3 ovarian cancer cells, VB18214 effectively inhibited cell proliferation (IC50 = 18.5 nM)." [DOI:10.1158/1538-7445.am2025-3021]
02
Targets
CDK2 (Cyclin-dependent kinase 2)
Beyond the preview
Go deeper on VB18214.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VB18214.